Leadership

CEO

Name Biography
James Jungkue Lee James Jungkue Lee founded Bridge Biotherapeutics Inc. in 2015 and currently serves as the CEO. After receiving his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. After his tenure at LG Chem, James co-founded Crystal Genomics where he led fundraising and business development activities. In 2008, he founded Rex Bio and successfully developed an antibody treatment for pancreatic cancer.

EVP

Name Biography
B. Christopher Kim, Ph.D., MBA B. Christopher Kim joined Bridge Biotherapeutics in March 2021, as an EVP leading Boston Discovery Center (BDC) and the US subsidiary of the company. Before joining Bridge as an EVP, he served as an outside director of the company from 2016 to 2021. He led corporate development, strategy and operations of NIBR and Global BioMarker Development group at Novartis. He then served as a partner at Oxford Bioscience Partners, a Boston based VC firm. He served as a managing director at Novatio Ventures and actively involved with life sciences companies globally. He received his PhD at the University of Texas MD Anderson Cancer Center and Health Science Center at Houston and MBA at Carnegie Mellon University.

SVP, Head of R&D

Name Biography
Yong-Hee Lee, Ph.D. Yong-Hee Lee serves as the Senior Vice President of Clinical Development at Bridge Biotherapeutics. After receiving his Ph.D. in Pharmacy at Seoul National University, he conducted research on ocular drug delivery at the University of South California. Additionally, he focused on the pre-clinical development of new drugs at LG Chem and Ligand Pharmaceuticals after which he was responsible for the development of several new drugs, in various stages (pre-clinical and clinical) of development, at Ikaria (currently Mallinckrodt) and Pfizer.

SVP, Head of Clinical Development

Name Biography
Sang-Uk Kang, Ph.D. Sang-Uk Kang serves as the Senior Vice President of Research and Development. After receiving his Ph.D. in Pharmacy at Seoul National University, he received his post-doctoral training at the National Cancer Institute in the US, focusing on the area of anti-cancer drugs and antibiotics. Sang-Uk was also involved in the discovery of anti-cancer and hepatitis C drugs at Rexahn and Sequoia, both biotech companies located in Maryland. Prior to joining Bridge Biotherapeutics, he served as a Senior Manager in new business development, medicinal chemistry, and CMC at Chemizon (now CMG Pharmaceuticals), Bukwang Pharmaceuticals, and Yuyu Pharmaceuticals.

VP, CMO

Name Biography
Sang-Yoon Lee M.D. Sang-Yoon Lee earned his M.D. from the College of Medicine at Seoul National University and completed his fellowship training in the division of Hematology and Oncology at Seoul National University Hospital. He served as JACK (Japan, Australia, Canada and Korea) Regional Medical Lead for crizotinib and Medical Affairs Director of Oncology Japan at Pfizer. He also worked at Samsung Bioepis, CrystalGenomics, HANDOK and Interpark Bio Convergence Corp., mainly leading early phase clinical development projects.

VP, Medical Leadership

Name Biography
Angela Yum, MD, ABPN Angela Yum earned her M.D. from the College of Medicine at Seoul National University and completed specialty training in psychiatry at the University of Medicine and Dentistry of New Jersey (New Jersey Medical School). She started her industry career 12 years ago as a clinical research physician at Lilly then progressed to become the global clinical program leader at Boehringer Ingelheim. She also participated in numerous in-licensing reviews as a clinician team member. 

VP, Head of
Discovery Biology

Name Biography
Jimmy Jin, M.D., Ph.D. Jimmy Jin serves as the Vice President and Head of Discovery Biology. After receiving his M.D. from the College of Medicine at Peking University in Beijing, China, he earned his Ph.D. in Molecular Biology from Kobe University in Japan and completed his postdoctoral fellowship at Harvard Medical School in Boston, USA. Prior to joining Bridge Biotherapeutics, he served as the Deputy Head of Discovery Oncology, pRED China at Roche and the Director of Translational Medicine Program Lead at Sanofi, both in Shanghai, China.